NCT05049538 Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
| NCT ID | NCT05049538 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Endometrial Clear Cell Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2019-06-18 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2019-06-18 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.
Eligibility Criteria
Inclusion Criteria: * Women age 18 years and older * Histologic diagnosis of endometrial cancer * Candidate for primary surgical treatment or has recently had prior primary surgery * Willing and able to provide informed consent Exclusion Criteria: Patients who have received prior treatment including chemotherapy or radiation therapy for endometrial cancer. Prior hormonal therapy for the treatment of endometrial cancer is allowed. Patients with prior primary surgery will be allowed to enroll in this trial if the patient has not received any chemotherapy or radiation at the time of enrollment. Note: patients with a history of other cancers may be enrolled after discussion with the PI if it is determined that they are at low risk for recurrence or metastasis.
Contact & Investigator
Pamela T Soliman
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT05049538 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Endometrial Clear Cell Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05049538 currently recruiting?
Yes, NCT05049538 is actively recruiting participants. Contact the research team at psoliman@mdanderson.org for enrollment information.
Where is the NCT05049538 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05049538 clinical trial?
NCT05049538 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Pamela T Soliman at M.D. Anderson Cancer Center. The trial plans to enroll 1,000 participants.